Last updated on December 2018

A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Peripheral T-Cell Lymphoma
  • Age: Between 20 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Patients with a Japanese, Korean, Taiwanese, or Chinese ethnic background of each country/region
  • Patients aged 20 years on the date of informed consent
  • Patients with histologically confirmed diagnosis of one of the following:
  • Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)
  • Angioimmunoblastic T-cell Lymphoma (AITL)
  • Anaplastic large cell lymphoma (ALCL), (ALK-positive/negative)
  • Relapsed or refractory patients with a treatment history of at least one regimen with antitumor agents for the above disease
  • Have at least 1 measurable lesion
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Patients with a life expectancy of at least 3 months as determined by the investigator

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.